Document is current
Any future updates will be listed below
-
Authors
Sayedipour, S. Sana https://orcid.org/0000-0002-6686-3074
Nikkels, Jelle
Tertel, Tobias https://orcid.org/0000-0001-8659-8610
Suchiman, Helena E. D. https://orcid.org/0000-0002-7168-5516
Koedam, Marijke
Balbi, Matilde https://orcid.org/0000-0002-9774-6786
Shaw, Georgina
Cruz, Luis J.
van der Eerden, Bram C. J. https://orcid.org/0000-0003-4403-6497
van der Weerd, Louise https://orcid.org/0000-0002-5997-2125
Gentili, Chiara https://orcid.org/0000-0001-6745-3782
Giebel, Bernd https://orcid.org/0000-0003-2446-948X
Murphy, Josephine Mary https://orcid.org/0000-0003-0971-7684
Meulenbelt, Ingrid https://orcid.org/0000-0001-7786-7081
Ramos, Yolande F. M. https://orcid.org/0000-0003-1459-413X
- License Information
-
More Information
Article History
Received: 15 August 2025
Accepted: 31 December 2025
First Online: 6 February 2026
Declarations
:
: The project “Dose finding & potential adverse effects observations in the DMM model” was conducted at the Leiden University Medical Center and was approved by the Animal Welfare Committee (IvD) under number AVD1160020171405- PE.18.101.006 on Apr 21, 2023. The Medical Ethics Committee of the LUMC gave approval for generation of hiPSCs from skin fibroblasts of healthy donors under number P13.080 on July 2 2014 (Parapluprotocol: hiPSC). Informed consent was obtained from all donors.
: Not applicable.
: The authors declare no competing interests.
